Trial Profile
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNF Alpha Agents
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Jan 2024
Price :
$35
*
At a glance
- Drugs Guselkumab (Primary)
- Indications Psoriatic arthritis
- Focus Registrational; Therapeutic Use
- Acronyms Discover-1
- Sponsors Janssen Research & Development; Janssen-Cilag
- 15 Nov 2023 Results of post hoc analysis (n=1120) assessing the effect of Guselkumab on time to minimal clinically important improvements (MCII) in patients reported outcomes and composite measures of disease activity and assessed association between W4/W8 MCII achievement and later disease control (W24/W52), presented at the ACR Convergence 2023.
- 15 Nov 2023 Results assessing the agreement of PtGA and PhGA through week (W) 24 and identified factors driving disagreement between PtGA and PhGA using pooled data from the phase 3 DISCOVER (D)1 & 2 studies, presented at the ACR Convergence 2023.
- 15 Nov 2023 Results of post hoc pooled analysis assessing the relationships between blood neutrophils and clinical outcomes during treatment with the fully human IL-23p19-subunit inhibitor guselkumab from DISCOVER-1 & 2 trials, presented at the ACR Convergence 2023.